🇰🇷🇨🇦🇺🇸 Medical Oncologist @MoffittNews | H&N/Endocrine Oncology | Early Therapeutics Development
Tampa, FL
Joined December 2014
- Tweets291
- Following334
- Followers340
- Likes714
Our latest manuscript in #AJCO explores 🩸 & intra-tumor NLR as prognostic biomarkers in pts with R/M HNSCC treated w/ combined cetux + nivo 💉 journals.lww.com/amjclinical… @MoffittNews @WinshipAtEmory @OSUCCC_James
✨Thrilled to be joining @MoffittNews! Will be starting as a H&N/Endocrine Oncologist with an early therapeutics development/translational research focus. Excited for what’s ahead!
✨Thrilled to be attending AACR-KCA 2024 in Seoul to present the long-term FU & biomarker results from our cetux/nivo trial in R/M HNSCC ✨ @MoffittResearch @MoffittNews 🔥Beyond grateful for the travel grant award @AACR 🙏
🔥Excited to see our review out in @MCT_AACR!✨ We highlight the unmet needs & emerging therapies in HPV- R/M HNSCC🎯Grateful for the mentorship & guidance from @CHChungMD✨@MoffittHemOnc @MoffittResearch aacrjournals.org/mct/article…
And thrilled to 👀 this work also just published 🔥Opportunity to work on this by Dr. Christine Chung 🙏 Check out 👉 Phase Ib trial of IRX-2 plus durvalumab in patients with R/M HNSCC. sciencedirect.com/science/ar…… @MoffittHemOnc @DrKedarKirtane
3
4
392
Will be missing out on #ASCO24😭 but super excited to see this published! Immensely grateful to Dr. @AnwaarSaeed3 for the opportunity🙏 Check out 👉 Immunotherapy in Colorectal Cancer — Finding the Achilles’ Heel | NEJM Evidence evidence.nejm.org/doi/full/1… @NEJMEvidence
Excited to see the results of CAMILLA CRC out on @NatureComms🔥Privileged for the opportunity to be part of the study ✨ Congrats Dr. Saeed!
🔥off the press: clinical & biomarker results of CAMILLA CRC cohort, positive outcome w differential advantage in RAS wild-type population. Insightful spatial transcriptomic findings laying the foundation for ongoing phase III STELLAR 303 trial ✨@UPMCHillmanCC @OncoAlert
Congrats Dr. Saeed on the encouraging results of the CAMILLA G/E cohort👏Privileged to be part of the study🙏 #GI24 @ASCO
#GI24 @ASCO CAMILLA G/E cohort of Cabo+Durva in MSS chemorefractory setting.
> considering 30% were IO refractory, results R encouraging.
> Impressive outcome in CPS >5 subgroup that won’t be seen w IO monotherapy & supports clinical synergy with the doublet 😇✨✨
@OncoAlert
👏Thank you @TumorBoardTues @JohnEbbenMDPhD @MPishvaian for hosting our discussion and helping us highlight this area of unmet need and active research! @AnwaarSaeed3
Good morning! ☕️ Huge thank you to @AnwaarSaeed3 & @rprobinpark for an excellent discussion at #TumorBoardTuesday this past week!
Excited to see KRAS/G12D inhibitors (in addition to new IO strategies) coming in the pipeline, and the role for NGS in the advanced line setting!
📢Join us @TumorBoardTues in our discussion on decision making for 3L Tx for mCRC
📺Tune in tonight @ 8 PM!
#CRC @AnwaarSaeed3 @UPMCHillmanCC @MoffittHemOnc
#TumorBoardTuesday
➡️We are in desperate need for somthing new, something better for refractory (>=3⃣rd line) metastatic #coloncancer
✅So this presentation by @AnwaarSaeed3 & @rprobinpark is so timely⏲️
📢Join us tomorrow 10/10/2023 at 8PM Eastern for a spirited🗣️
🔥Early-phase trials support RAS as a potential predictive marker for ICI regimens in MSS #CRC. ✨Mentorship from @AnwaarSaeed3 ➡️Check out our editorial #ASCODailyNews dailynews.ascopubs.org/do/ra… @UPMCHillmanCC #ASCODailyNews @ASCO
Ph III trial tailored towards the RAS wt population to answer the❓👉 ascopubs.org/doi/abs/10.1200…
1
257
Pub alert !!🚨
CAMILLA Ph 1b results out in @CellRepMed !! ✨
➡️Cabozantinib/Durvalumab has activity & tolerable safety in advanced MSS GI ca. @AnwaarSaeed3
➡️Subsequent Ph 2/3 studies ongoing. @UPMCHillmanCC
🔥off the press: phase 1b results of CAMILLA showing Cabo plus Durva is a safe, active, & potentially synergistic regimen in MSS GI malignancies. Ongoing phase II & III trials stemming from this first report ✨✨ @CellPressNews @CellRepMed @UPMCHillmanCC @rprobinpark @OncoAlert
Excited to see the abstracts drop #GI22! (Virtually) presenting our analysis on the long-term hematologic toxicities of TMZ w/ potential implications in duration of Tx in NENs 🦓 @NTrikalinos @ManikAmin4 Check out 👉 meetings.asco.org/abstracts-…
Beyond excited to have matched @MoffittNews for hematology/oncology fellowship! Immense thanks to everyone who has guided and supported me along the way. Thrilled to know that I’m going to be a hematologist/oncologist!
11
46
Excited to see our paper out! Growing body of literature showing that immune checkpoint molecules are also important regulators of bone resorption and remodeling✨🌟 @UniversityKorea @Naturepub nature.com/articles/s41419-0…
Can’t wait for ASCO21⭐️ Excited to present our abstract ⬇️ BRAF mutations in MSI-H CRC @laerciolopesMD @AnwaarSaeed3
Case report: An exceptional erlotinib responder with EGFR exon-19-deleted PDAC. @AnwaarSaeed3 sciencedirect.com/science/ar…
Excited to present our RVW on IO+VEGF targeted agents in GC/GEA! @AnwaarSaeed3 @JHOON @SN_Oncology #Immunotherapy #VEGF jhoonline.biomedcentral.com/…